Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Acquisitions Expand Verano’s Footprint to 14 States, 15 Cultivation and Production Facilities, and 150 Dispensaries Nationwide CHICAGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Verano Holdings Corp...
Dana Holding Set to Join the S&P MidCap 400 PR Newswire NEW YORK, Jan. 20, 2015 NEW YORK, Jan. 20, 2015 /PRNewswire/ -- Dana Holding Corp. (NYSE: DAN) will replace Cubist Pharmaceuticals Inc...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will voluntarily withdraw the contingent value rights (CVRs) it issued under a Contingent Value Rights Agreement dated...
ZERBAXA geht bestimmte gefährliche und resistente gramnegative Bakterien anErstes in den USA unter dem GAIN-Gesetz zugelassenes Antibiotikum gegen gramnegative Bakterien Cubist...
ZERBAXA s’attaque à certaines bactéries à Gram négatif graves et résistantes Premier nouvel antibiotique approuvé aux États-Unis dans le cadre de la GAIN Act pour le traitement des...
ZERBAXA addresses certain serious and resistant Gram-negative bacteriaFirst new antibiotic approved in U.S. under the GAIN Act that treats Gram-negative bacteria Cubist...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender to purchase all outstanding shares of common stock of Cubist...
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company PR Newswire BALA...
CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.08 | 0.09 | 0.0675 | 1231663 | 0.075 | CS |
| 4 | -0.075 | -48.3870967742 | 0.155 | 0.155 | 0.0675 | 831036 | 0.0863655 | CS |
| 12 | -0.215 | -72.8813559322 | 0.295 | 0.355 | 0.0675 | 714634 | 0.16190136 | CS |
| 26 | -0.185 | -69.8113207547 | 0.265 | 0.42 | 0.0675 | 554621 | 0.22778952 | CS |
| 52 | -0.49 | -85.9649122807 | 0.57 | 0.83 | 0.0675 | 1014502 | 0.43525513 | CS |
| 156 | -1.6 | -95.2380952381 | 1.68 | 1.76 | 0.0675 | 1074313 | 0.54258874 | CS |
| 260 | -1.6 | -95.2380952381 | 1.68 | 1.76 | 0.0675 | 1074313 | 0.54258874 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
